Clinical Research Directory
Browse clinical research sites, groups, and studies.
Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer
Sponsor: Chinese PLA General Hospital
Summary
The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer. The main questions it aims to answer are: * Does the duration of neoadjuvant treatment influence tumor regression grading (TRG)? * How does treatment duration affect perioperative safety and clinical outcomes? Participants who have previously undergone neoadjuvant PD-1 inhibitor combined with chemotherapy followed by surgery as part of their routine medical care will have their clinical data retrospectively reviewed and analyzed.
Official title: The Comparison of Different Cycles of PD-1 Blockades Combined with Chemotherapy As Neoadjuvant Therapy for Patients with Advanced Gastric Cancer
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2025-01-16
Completion Date
2025-01-31
Last Updated
2025-01-29
Healthy Volunteers
No
Conditions
Interventions
≤4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy
Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no more than 4 cycles
≥5 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy
Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no less than 5 cycles
Gastrectomy
Any type of surgical procedure for gastric adenocarcinoma patients in which part or all of the stomach is removed
Locations (1)
Chinese PLA General Hospital
Beijing, China